Waxman to Head Hey House Committee
In the Obama administration, an important ally in the House for Tom Daschle, who is expected to be named secretary of the Department of Health and Human Services, will be Rep. Henry Waxman (D-CA), who unseated John Dingell (D-MI), the long-time top Democrat on the House Energy and Commerce Committee, to become the panel’s new chairman.
In the Obama administration, an important ally in the House for Tom Daschle, who is expected to be named secretary of the Department of Health and Human Services, will be Rep. Henry Waxman (D-CA), who unseated John Dingell (D-MI), the long-time top Democrat on the House Energy and Commerce Committee, to become the panel’s new chairman. The House Democratic caucus backed Waxman for the job after a hotly contested campaign in which Waxman claimed to be better positioned to work with the new Obama administration to enact environmental and healthcare legislation.
The change puts a long-time critic of the pharmaceutical industry at the helm of this all-important panel. All healthcare legislation falls under its purview, along with measures affecting FDA and other federal health agencies. Both Dingell and Waxman have long championed universal healthcare, but differed more notably on environmental and clean air policy. A top priority for the new chairman will be to pursue health reform legislation vigorously.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
